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Objective: The present work offers a fast, reliable and easy UV spectrophotometric method for the assay of strontium ranelate from bulk 
samples and pharmaceutical dosage form. 
Methods: The proposed method uses 0.1% V/V trichloroacetic acid as dissolution medium for spectrophotometric analysis, by signal detec-
tion at 321 nm. The method was validated according to the currently in-force international guidelines for linearity, accuracy, precision, robust-
ness, limit of detection and quantification.
Results: The method was found to be linear in the range of 5-100 µg mL-1 (R2 > 0.999). Method accuracy was found in-between 98.87-
100.41%, showing good linear correlation as well (R2 = 0.9997). The concentrations for limit of detection and limit of quantitation were found 
1.13 µg mL-1 and 3.77 µg mL-1, resp. The proposed method showed good intra- and interday precision, with low RSD values of 0.53-1.24% 
and 1.11%, resp.
Conclusions: Stability studies performed by both HPLC and UV spectrophotometric methods revealed that the active substance is highly 
susceptible to acidic hydrolysis, oxidation and exposure to high temperature.
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Introduction
Strontium ranelate (SrR, Protelos, Osseor), chemically is 
the di-strontium salt of 2-(2-carboxy-4-cyano-5-[N,N-
di(carboxymethyl)amino]thiophene-3-yl) acetic acid 
(ranelic acid) (Fig. 1), is used in the treatment of post-
menopausal osteoporosis, having a positive risk/benefit 
ratio, and represents a viable alternative when medication 
with other anti-osteoporotic agents is futile [1]. The active 
substance is freely soluble in aqueous media at pH < 2, 
presenting a decreasing solubility by reaching the neutral 
domain. It is practically insoluble in organic solvents [2].
Literature data revealed that only a few UV spectro-
photometric methods have been reported for strontium 
ranelate so far [3-6]. Further analytical methods imply RP-
HPLC determination [7-10] and capillary zone electro-
phoresis [11] for the determination of the active substance.
According to the guidelines Q1A (R2) and Q1B pub-
lished by the International Conference on Harmonization, 
the forced degradation studies of the active substances are 
helpful for the identification of the possible degradation 
products and also may be applied for the evaluation of 
the intrinsic stability of the molecule. The stress stability 
* Correspondence to: Béla Kovács
E-mail: kovacsbela89@gmail.com
Fig. 1. Chemical structure of strontium ranelate
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testing of an active substance according to the mentioned 
directives should include the effect of temperature, humid-
ity, oxidative conditions, photolysis and hydrolysis across a 
wide pH range. Also, it is specified that photolysis should 
be performed under a light source which provides an illu-
mination greater than 1.2 million lux, and an energy in the 
near UV of not less than 200 Wh/m2 [12,13].
Taking into consideration that the already available UV 
spectrophotometric methods for the assay of strontium 
ranelate use a multicomponent solvent system, having a 
prolonged sample preparation time, our main objective 
was to develop and validate a high throughput, cost-effec-
tive and accessible method for the assay of strontium rane-
late from both bulk samples and pharmaceutical dosage 
form. Moreover, we aimed to test the stability of the active 
substance in accordance with the currently in-force inter-
national guidelines with two different analytical methods 
using an already available HPLC method and the currently 
presented UV spectrophotometric method.
Material and methods
Reagents
Strontium ranelate (SrR) standard was purchased from 
Sigma Aldrich (St. Louis, USA) and bulk active pharma-
ceutical ingredient (strontium ranelate octahydrate) was 
obtained from Dishman Pharmaceuticals and Chemicals 
(Ahmedabad, India). Trichloroacetic acid (TCAA) and 
trifluoroacetic acid (TFA) was used from Merck (Darm-
stadt, Germany). Water, purified was obtained by means 
of a Milli-Q water purification system (Millipore, Merck, 
Germany). Osseor® 2-g granules for oral suspension (Lés 
Laboratoires, Serviér, France) was purchased from lo-
cal pharmacies. Selectivity studies were performed using 
mannitol (Pearlitol 300DC, Ph. Eur., Roquette Pharma, 
France), maltodextrin (Lycatab DSH, Ph. Eur., Roquette 
Pharma, France) and aspartame (Ph. Eur., Sigma Aldrich, 
USA), excipients of the original product.
Preparation of standard solution
Standard solution was prepared by dissolving 4 mg SrR in 
TCAA 0.1% V/V solution in a 100 mL volumetric flask, 
and completed to the mark with the same solution, obtain-
ing a final concentration of 40 µg mL-1.
Apparatus and spectrophotometric method
UV spectrophotometric determination was performed 
using a Shimadzu 1800 UV-VIS (Shimadzu Co., Kyoto, 
Japan) spectrophotometer, special optical glass (OS type, 
Hellma Analytics, Müllheim, Germany) cuvettes with an 
optical path of 10 mm. For the evaluation of the optimal 
determination wavelength a scanning run (200-400 nm) 
was carried out and TCAA 0.1% V/V was used as a blank 
solution. For robustness studies a Labomed UVD-3200 
(Labomed Inc., Los Angeles, USA) spectrophotometer was 
used for comparison. Furthermore, method robustness was 
tested for the type of the cuvettes used for routine analysis, 
as the specification of OS type cuvettes indicates that it 
is useable in the range of 320-2500 nm. Absorbance of 
SrR stock solution was evaluated for both OS type and QS 
(Suprasil® quartz glass, Hellma Analytics, Müllheim, Ger-
many) type cuvettes, for which the recommended working 
interval is greater, lying between 200-2500 nm.
Method validation
Linearity. – Method linearity was assessed in the range of 
5-100 µg mL-1 in seven points (5, 10, 20, 40, 60, 80, 100 
µg mL-1), repeated five times for each concentration. So-
lutions were prepared by dilution with TCAA 0.1% V/V 
from a stock solution of 100 µg mL-1.
Selectivity – The selectivity of the method was inves-
tigated considering the quantitative and qualitative com-
position of Osseor® 2g granules for oral suspension. Pla-
cebo formulation was prepared using 4.0 g mannitol, 0.4 
g maltodextrin, and 0.02 g aspartame per dose. Selectivity 
was evaluated by comparing the absorbance spectrum of 
individually prepared samples of the excipients, placebo 
mixture, and placebo spiked with SrR. All samples were 
prepared under the same conditions using TCAA 0.1% 
V/V as dissolution medium.
Accuracy (recovery) – The accuracy of the method was 
tested using placebo mixture samples spiked with SrR, at 
five concentration levels (50%, 75%, 100%, 125%, and 
150%) of the working concentration, repeated three times 
for each concentration.
Robustness – Method robustness was verified for indi-
vidual changes in detection wavelength (321 nm ± 2 nm), 
temperature (4ºC vs. 25ºC), instrumentation (Shimadzu 
1800 vs. Labomed UVD-3200), pH (2.0 ± 0.2) and cu-
vette type (OS vs. QS).
Precision – The precision of the method was evaluated 
for both intraday- (repeatability) and intermediate preci-
sion. Six individual samples were prepared on the same day 
and on two different days by two analysts. Samples were 
prepared from Osseor® 2g granules corresponding to 3.12 
mg SrR anhydrous.
Limit of detection (LOD) and limit of quantification 
(LOQ) – LOD and LOQ were calculated from the cali-
bration plot as 3.3σ/S and 10σ/S, resp., where σ is the 
standard error of the intercept and S represents the slope of 
the calibration plot.
Statistical analysis
Statistical analyses were carried out using Minitab 17.0 
(Coventry, UK) and Statistica 8.0 (Tulsa, USA) software 
for the validation of the UV spectrophotometric method.
Method linearity and the normal distribution of the re-
siduals was tested using the Shapiro-Wilk’s test (confidence 
interval of 95%). Statistical significance was considered if 
both of the following criteria are met: the W value for SrR 
was greater than the critical tabulated value and p > 0.05. 
ANOVA F-test and its test for lack of fit (confidence limit 
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of 95%) was used for the assessment of the significance of 
the calibration curve.
Student’s t-test was used for statistically evaluating the 
intraday and intermediate precision results (confidence 
level of 95%).
Stress stability testing
Stability testing was performed for acidic – (with 0.1 M 
HCl) and alkali hydrolysis (with 0.1 M NaOH), oxidative 
stress (3% H2O2), thermal degradation (60ºC and 120ºC 
for 2 h) and photolysis (under a 125W UV lamp for 2 h). 
For the acidic –, and alkali hydrolysis, oxidative stress con-
ditions three samples, with two replicates were prepared 
individually for time points of 1, 2 and 7 days. Thermal 
degradation and photolysis studies were also performed 
from two replicate samples under the specified conditions.
Sample preparation for HPLC determination – for sta-
bility testing 4 mg of SrR and 6.24 mg of Osseor® were 
weighed in 50 mL volumetric flasks. For acidic and alkali 
hydrolysis and oxidative stress conditions 2 mL of 0.1 M 
HCl, 0.1 M NaOH and 3% H2O2 were added, resp. The 
samples were held in closed dark chambers until sampling. 
Before analysis, the samples were completed with TFA 
0.1% V/V, stirred on an ultrasound bath for 2 minutes 
and filtered through a 0.45-µm Whatman® nylon filter 
(General Electric Healthcare, UK) in brown HPLC vials. 
The first 2 mL of the filtered solution were discarded. For 
thermal degradation studies and photolysis the volumetric 
flasks were completed with TFA 0.1% V/V after weigh-
ing, stirred on an ultrasound bath for 2 minutes and fil-
tered through a 0.45-µm Whatman® nylon filter in brown 
HPLC vials, prior to analysis.
Sample analysis was performed according to the method 
described by Kovács et al. [9].
Sample preparation for UV spectrophotometric deter-
mination - for stability testing 4 mg of SrR and 6.24 mg 
of Osseor® were weighed in 50 mL volumetric flasks. For 
acidic and alkali hydrolysis and oxidative stress conditions 
2 mL of 0.1 M HCl, 0.1 M NaOH and 3% H2O2 were 
added, resp. The samples were held in closed dark chambers 
until sampling. Before analysis, the samples were complet-
ed with TCAA 0.1% V/V. For thermal degradation studies 
and photolysis the volumetric flasks were completed with 
TCAA 0.1% V/V after weighing.
Results and discussion
Absorption spectrum and selectivity. – The absorption spec-
trum of the stock solution revealed that strontium ranelate 
has an absorbance maximum at λ = 321 nm. Selectivity 
studies elucidated that there is no interference between 
strontium ranelate and the selected excipients at λ = 321 
nm. Furthermore, no change in absorbance maximum was 
observed between the two types of cuvettes tested (Fig. 2).
Linearity. – The method was found to be linear in the 
range of 5-100 µg mL-1 (R2 = 0.9999). The normal dis-
tribution of residuals was evaluated by the Shapiro-Wilk’s 
test, indicating that the residuals follow a normal distribu-
tion, as the WSrR is greater than the critical tabulated value, 
Wc, and p > 0.05.
Accuracy (recovery). – The recovery of placebo spiked 
samples were found between 98.87-100.41% for the tested 
range of 50-150% of the working concentration, fulfill-
ing the requirements of international standard to be in-
between 95-105%. The mean recovery was found to be 
99.24%. The linearity of the tested samples showed a good 
correlation with R2 = 0.9997.
Robustness. – The method was found to be robust for 
all tested changes, the obtained concentrations lying be-
tween 98.23-102.16%.
Method precision. – The precision of the method re-
turned low RSD% values for both the intraday (0.53-
1.24%) and intermediate precision (1.11%).
Limit of quantification and limit of detection. – Based 
on the regression analysis LOD and LOQ values were cal-
culated, resulting in 1.13 µg mL-1 and 3.77 µg mL-1, resp.
The presented method offers a greater linearity interval 
in comparison to the already available UV-spectrophoto-
metric methods for the assay of strontium ranelate, where 
depending on the dissolution medium and method pecu-
liarities linearity ranges of 2-20 µg mL-1 [3], 4-28 µg mL-1 
[4], 5-55 µg mL-1 [5] and 5-50 µg mL-1 [6] are reported. 
Although the current method only approximates the low-
er limits of the disclosed methods (5 µg mL-1 vs. 2-4 µg 
mL-1), the upper limit is substantially superior when com-
pared to literature data (100 µg mL-1 vs. 50-55 µg mL-1). 
Method accuracy shows similar recovery intervals to the 
referred methods. Our method is more bounded regard-
ing the LOD and LOQ values (1.13 µg mL-1 and 3.77 µg 
mL-1, resp.) when compared e.g. to the values presented 
Fig. 2. Absorbance spectrum of strontium ranelate using QS (special quartz) and OS (special optic) type cuvettes
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by Swami et al. [4] of 0.013 µg mL-1 and 0.043 µg mL-1 
for LOD and LOQ, resp. Finally, as the previous studies 
lack the robustness testing of the method, the newly de-
veloped technique assessed the impact of general variables 
(detection wavelength, instrumentation, cuvette type) on 
method performance and tested them during the valida-
tion procedure (Table I).
Stress stability testing. – The active substance proved to 
be highly susceptible to acidic hydrolysis, oxidative stress 
and thermal degradation, especially at high temperatures. 
Alkali conditions, UV light or lower thermal impact has 
only a negligible effect on the stability of SrR. The results 
are in concordance with the finding presented by Swami et 
al. [7], as the active substance subjected to acidic hydrolysis 
and oxidative stress (1 M HCl and 3% H2O2 for ½ hour) 
presents high degradation (77.15% and 80.89%, resp.), 
whilst under thermal impact (60°C for ½ hour), alkali 
hydrolysis (1 M NaOH for ½ hour) and UV irradiation 
(24 hours) only slight decomposition of SrR was observed 
(94.77%, 97.59% and 98.19%, resp.).
The stability testing results are similar to the ones ob-
tained in our previous HPLC studies [9]. The degradation 
profile presents the same level, to a certain extent, regard-
ing hydrolysis, oxidative and photolytic studies for both 
HPLC and UV-spectrophotometric determinations (Table 
II and III).
Conclusions
The presented UV spectrophotometric method proved to 
be adequate for the routine analysis of strontium ranelate 
Table III. Stress stability test results of strontium ranelate bulk samples and Osseor® by UV-spectrophotometry
Strontium ranelate bulk sample, % of degradation by UV spectrophotometry
Stock solution NaOH 0.1M HCl 0.1M H2O2 3%
Thermal degradation
UV light exposure
60ºC / 2h 105ºC / 24h
Day 1 2.26 Nil 8.24 3.74
9.90 87.87 3.20Day 2 7.69 Nil 12.91 9.59
Day 7 25.73 0.95 26.60 61.25
Osseor® samples, % of degradation by UV spectrophotometry
Stock solution NaOH 0.1M HCl 0.1M H2O2 3%
Thermal degradation
UV light exposure
60ºC / 2h 105ºC / 24h
Day 1 2.53 Nil 2.48 3.27
14.24 97.98 2.86Day 2 7.70 Nil 11.11 6.91
Day 7 17.40 0.72 26.55 50.34
Table I. Analytical merits of the developed UV-spectrophotometric method
Parameter Results Statistical results
Linearity (µg mL-1)
5-100
(y = 0.0242x + 0.0116)
R2 = 0.99991 (n=7)
WSrR = 0.911 (p = 0.40)a
Cpk = 2.43d
Accuracy (%) 98.87-100.41 R2 = 0.9997 (n=5)
Intraday precision (RSD, %), n=6 0.53-1.24
t analyst 1, day 1 vs. analyst 2, day 1 = 1.546 (p = 0.15)b
t analyst 1, day 2 vs. analyst 2, day 2 = 0.656 (p=0.53)b
Inter-day precision (RSD, %), n=24 1.11
t analyst 1, day 1 vs. analyst 2, day 2 = 0.580 (p = 0.57)b
t analyst 1, day 1 vs. analyst 1, day 2 = 0.298 (p = 0.77)b
t analyst 1 vs. analyst 2  = 1.614 (p = 0.12)c
Instrument precision (RSD, %) 0.33 -
LOD (µg mL-1) 1.13 -
LOQ (µg mL-1) 3.77 -
a Wc = 0.850, critical value of Shapiro-Wilk’s test; b Critical value of t = 2.228, df = 10; c Critical value of t = 2.074, df = 22; d Cpk > 1.33 (limit of acceptance for process capability)
Table II. Stress stability test results of strontium ranelate bulk samples and Osseor® by RP-HPLC
Strontium ranelate bulk sample, % of degradation by HPLC
Stock solution NaOH 0.1M HCl 0.1M H2O2 3%
Thermal degradation UV light  
exposure60ºC / 2h 105ºC / 24h
Day 1 3.55 Nil 8.11 8.20
17.19 100.00 2.70Day 2 9.32 Nil 10.54 27.96
Day 7 31.97 0.96 37.75 43.02
Osseor® samples, % of degradation by HPLC
Stock solution NaOH 0.1M HCl 0.1M H2O2 3%
Thermal degradation UV light  
exposure60ºC / 2h 105ºC / 24h
Day 1 3.65 Nil 6.80 8.97
4.38 100.00 0.26Day 2 6.76 Nil 9.86 32.13
Day 7 23.61 0.59 35.65 57.84
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from both bulk samples and pharmaceutical dosage forms. 
The method offers a high throughput, low cost sample 
measurement, using conventional apparatus and single 
component solvent system (TCAA 0.1%). The validated 
method according to the currently in-force international 
guidelines presents an appropriate linearity in the range of 
5-100 µg mL-1 and a mean recovery of 99.24%. Moreover, 
the method proved to be applicable regardless of the type 
of cuvettes, thus might ease the analytical transfer between 
control laboratories. Furthermore, taking into consider-
ation the precision of the method validated from Osseor® 
2 g granules for oral suspension, this determination might 
represent an alternative to the currently available analyti-
cal methods. Both the HPLC and UV spectrophotometric 
methods proved to be adequate for the determination of 
the degradation profile of strontium ranelate, the method 
having its limitations in the quantification of the formed 
impurities. The stability studies of the active pharmaceuti-
cal ingredient from both bulk samples and pharmaceutical 
dosage form revealed that it is highly susceptible to acidic 
hydrolysis, oxidative stress and heat being slightly influ-
enced in alkali media and UV light exposure.
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